Ergomed plc Total Voting Rights (8015K)
September 02 2019 - 2:00AM
UK Regulatory
TIDMERGO
RNS Number : 8015K
Ergomed plc
02 September 2019
PRESS RELEASE
Total Voting Rights
Guildford, UK - 2 September 2019: In accordance with the
Financial Conduct Authority's Disclosure Guidance and Transparency
Rules ("DTRs"), Ergomed plc (the "Company") announces the following
information.
The Company's issued share capital as at 31 August 2019
consisted of 47,098,576 ordinary shares of 1p each, none of which
were held in treasury. Each ordinary share in the capital of the
Company carries one voting right.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the Company, under the DTRs.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated
Adviser)
James Black (Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical trials, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services business includes a full range of high-quality
contract research and trial management (CRO) services under the
Ergomed brand together with an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, and an internationally recognised specialist
expertise in orphan drug development, under the PSR brand. For
further information, visit: http://ergomedplc.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRLBMMTMBJMTIL
(END) Dow Jones Newswires
September 02, 2019 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2023 to Apr 2024